Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed Conditions

This study has been completed.
Sponsor:
Information provided by:
Ranbaxy Inc.
ClinicalTrials.gov Identifier:
NCT00779805
First received: October 23, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

The objective of the study was to compare the single dose oral bioavailability of Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy with Sudafed 120 mg ER tablets of Pfizer Consumer Health Care in healthy, adult, human subjects under fed conditions.


Condition Intervention
Healthy
Drug: Pseudoephedrine hydrochloride 120 mg ER tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Pseudoephedrine Hydrochloride Formulations Comparing Pseudoephedrine Hydrochloride 120 mg ER Tablets of Ranbaxy Laboratories With Sudafed 120 mg ER Tablets of Pfizer Consumer Health Care in Healthy, Adult, Human Subjects Under Fed Conditions.

Resource links provided by NLM:


Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Bioequivalence [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: June 2004
Study Completion Date: October 2004
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
Drug: Pseudoephedrine hydrochloride 120 mg ER tablets
Active Comparator: 2
Sudafed 120 mg ER tablets
Drug: Pseudoephedrine hydrochloride 120 mg ER tablets

Detailed Description:

This study was an open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioavailability study planned on 40 healthy, adult, human subjects under fed conditions.

A total of forty (40) healthy, adult, human subjects were admitted in the study to allow the dosing in the first period. Out of the forty subjects, only thirty eight (38) subjects completed both the periods of the study.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be in the age range of 18 - 45 years
  • Be neither over weight nor under weight for his/ her height as per the Life Insurance Corporation of India height/ weight chart for non-medical cases
  • Have voluntarily given written informed consent to participate in this study
  • Be of normal health as determined by medical history and physical examination of the subjects performed within 14 days prior to the commencement of the study
  • If female and:
  • Of child bearing potential is practicing an acceptable method of birth control for the duration of the study as judged by the investigator (s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or
  • Is postmenopausal for at least 1 year; or
  • Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)

Exclusion Criteria:

  • History of allergy to Pseudoephedrine or other sympathomimetic drugs
  • History of intake of any sympathomimetic drugs and glucocorticoids during a period of 15 days prior to day 1 of this study.
  • Concurrent use of monoamine oxidase inhibitor (MAOI) drugs within 14 days prior to day 1 of this study
  • Any evidence of organ dysfunction or any clinically significant deviations from the normal, in physical or clinical determinations
  • Presence of disease markers of HIV 1 or 2, hepatitis B or C viruses or syphilis infection
  • Female volunteers demonstrating a positive pregnancy test
  • Female volunteers who are currently breastfeeding
  • Presence of values which are significantly different from normal reference ranges (as defined in appendix 5) and/ or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol
  • Clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (>4/ HPF), glucose (positive) or protein (positive)
  • Clinically abnormal ECH or chest X-ray
  • History of serious gastrointestinal, hepatic, renal, pulmonary, neurological or hematological diseases or glaucoma
  • History of cardiovascular disorders (including hypertension), endocrine disorders, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, palpitations, insomnia, tremors or bronchial asthma
  • History of any psychiatric illness which may impair the ability to provide written informed consent
  • Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
  • History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the duration of each study period
  • Use of any enzyme modifying drugs within 30 days prior to day 1 of this study
  • Participation in any clinical trail within 12 weeks preceding day 1 of this study
  • Subjects who, through completion of this study, would have donated and / or lost more than 350 mL of blood in the past 3 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00779805

Locations
India
Ranbaxy CPU
Gurgaon, Haryana, India
Sponsors and Collaborators
Ranbaxy Laboratories Limited
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Tausif Monif, Ranbaxy Research Labs
ClinicalTrials.gov Identifier: NCT00779805     History of Changes
Other Study ID Numbers: 016/ PSEUD-120/ 04
Study First Received: October 23, 2008
Last Updated: October 23, 2008
Health Authority: India: Drugs Controller General of India

Keywords provided by Ranbaxy Inc.:
Bioequivalence Pseudoephedrine hydrochloride 120 mg ER tablets

Additional relevant MeSH terms:
Pseudoephedrine
Ephedrine
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Nasal Decongestants
Vasoconstrictor Agents
Cardiovascular Agents
Central Nervous System Stimulants
Central Nervous System Agents
Sympathomimetics
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014